Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

NeuroLF

Financiado

NeuroLF The best small and mobile dedicated brain PET scanner for an accessibl...

NeuroLF The best small and mobile dedicated brain PET scanner for an accessible early detection of Alzheimer s disease Dementia affects around 50 M people globally (mainly over 65 years old) and has high associated costs (~ $1 trillion per year). 60%-80% cases correspond to Alzheimer’s Disease (AD), which is expected to continue increasing exponen... ver más

30/09/2022

Positrigo AG

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

POSITRIGO AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-09-30

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 6 años

0% 100%

2 Participantes

Positrigo AG

2.25M€ | Lider

RINGO VALVULAS

471.52K€ | Participante

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 27 meses Fecha Inicio: 2020-06-08
Fecha Fin: 2022-09-30

Líder del proyecto

POSITRIGO AG

TRL 4-5

Presupuesto del proyecto 3M€

Descripción del proyecto Dementia affects around 50 M people globally (mainly over 65 years old) and has high associated costs (~ $1 trillion per year). 60%-80% cases correspond to Alzheimer’s Disease (AD), which is expected to continue increasing exponentially in the next decades. At present, there are several disease-modifying treatments for AD in development, but once approved they will demand an efficient early detection of the disease to be effective. PET is the gold standard for prompt detection of AD's biomarkers (e.g. beta-amyloid and tau proteins), but traditional scanners are very big and expensive and they do not allow wide-population screenings. Positrigo is a Swiss start-up, aiming to develop NeuroLF brain PET system, which is only a tenth of the price (reduced device, personnel and radiotracers costs) and a fifth of the size of traditional scanners. It will allow to meet the expected large increase in PET examinations in the incoming years (when new treatments are approved) and make brain scanning affordable for everyone. NeuroLF was developed with support from ETH Zurich, University of Zurich and University of Heidelberg, and thanks to decades of accumulated experience in particle physics from the team. The company also counts with world-class advisors for business and medical aspects. Our potential market, based on the need for Alzheimer’s diagnosis for population older than 50 years, gives us around 20 M scans per year only in USA and the EU. Moreover, 1 NeuroLF scanner working at full capacity represents savings of about $ 200.000 per year for healthcare. We have developed the first prototype and preliminary tested standard performance parameters, as well as initially established in-house manufacturing, defined a regulatory roadmap, contacted some key stakeholders and identified the needs on optimization, clinical validation and successful market launch. Now, to successfully begin NeuroLF commercialization, we need further funding and we are asking for support from the EC.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores